A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

NCT Number	NCT06807281
Lead Sponsor	Pfizer
Conditions	Atopic Dermatitis
Enrollment	500 participants
Start Date	2025-12-02
Primary Completion	2032-02-22 (estimated)
Study Completion	2032-02-22 (estimated)
Updated on ClinicalTrials.gov	2026-04-07